Screening Libraries
| Cat. | Size | Price | Stock | |
| L20205 | 1mg/well * 2 Compounds | Inquiry | In stock | Contact Us |
| L20205 | 100uL/well (10mM solution) * 2 Compounds | Inquiry | In stock |
| manager@chemfaces.com | |
| Tel | (0086)-27-8423-7683 |
| Shelf Life | (0086)-27-84254680 |
| Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
| Container | 96 Well Format Sample |
| Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
| Shelf Life | 24 months (2-8 °) |
| Intended Use | For research use only. Not for human use. Not sell to patients |
| 1. The products in the ChemFaces screening libraries are all from plants. |
| 2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
| 3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
| 4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
| 5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
| Catalog No. | Information |
| CFN99694 | Brevilin A Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM). |
| CFN00141 | Tirandamycin A Tirandamycin A and echinomycin A have anti-amoebic properties, they inhibit the in vitro growth of a E. histolytica laboratory strain (HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30- to 60- uM concentrations. Tirandamycin A and streptolydigin possess potent antibacterial activity particularly against anaerobes, have been shown to inhibit bacterial RNA polymerase. |
